Patents Assigned to Secretary, Department of Health & Human Services
  • ZIKA VIRAL ANTIGEN CONSTRUCTS
    Publication number: 20230242593
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.
    Type: Application
    Filed: September 16, 2022
    Publication date: August 3, 2023
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: KIMBERLY DOWD, BARNEY S. GRAHAM, SUNG-YOUL KO, WING-PUI KONG, JOHN MASCOLA, THEODORE PIERSON, MAYURI SHARMA, DONG YU
  • Conformational restriction of cyanine fluorophores in far-red and near-IR range
    Patent number: 11707537
    Abstract: Conformationally restricted cyanine fluorophores, as well as methods of making and using the compounds, are described. The conformationally restricted cyanine fluorophores have a chemical structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof: wherein A is and wherein each “*” designates an attachment point of A.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: July 25, 2023
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin J. Schnermann, Megan S. Michie
  • Compositions and methods for treating cancer with anti-CD19 immunotherapy
    Patent number: 11708408
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: July 25, 2023
    Assignees: Lentigen Technology Inc., The U.S.A. as represented by the Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Rapid detection of Zika virus by reverse transcription loop-mediated isothermal amplification
    Patent number: 11708613
    Abstract: A highly sensitive and specific reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay to detect ZIKV nucleic acid in biological samples is described. The disclosed assay is capable of detecting as few as one RNA copy per ?l and can be performed in a clinical or field setting with minimal equipment and technological expertise. Oligonucleotide primers and kits for detecting ZIKV nucleic acid are also described.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 25, 2023
    Assignee: The United States of America, as Represened by the Secretary, Department of Health and Human Services
    Inventor: Amanda E. Calvert
  • MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20230227492
    Abstract: Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogenic, androgenic, and estrogenic activity, which can prevent or inhibit bone density loss in subjects. Oligomeric compound embodiments disclosed herein provide the ability to control receptor activation and/or treatment by incorporating a tunable linker group which couples steroidal-based compounds to one another or with therapeutic agents and facilitates selective cleavage of the monomeric components of the oligomeric compound.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 20, 2023
    Applicants: The USA as represented by the Secretary, Department of Health and Human Services, Ash Stevens, LLC
    Inventors: Min Lee, Diana Blithe, Ming-Teh Lin, Pranab Gupta, Bashir Kaskar
  • Compounds for improving mRNA splicing
    Patent number: 11702417
    Abstract: Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: July 18, 2023
    Assignees: The General Hospital Corporation, The United States Of America, as represented by the secretary, Department of Health and Human Services
    Inventors: Susan A. Slaugenhaupt, Graham Johnson, William D. Paquette, Wei Zhang, Juan Marugan
  • Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors
    Patent number: 11702472
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: July 18, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • CANNABINOID RECEPTOR MEDIATING COMPOUNDS
    Publication number: 20230219896
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Application
    Filed: February 10, 2023
    Publication date: July 13, 2023
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Anti-human papillomavirus 16 E6 T cell receptors
    Patent number: 11697676
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: July 11, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Nanoparticle to target cancer
    Patent number: 11696922
    Abstract: A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: July 11, 2023
    Assignees: Georgetown University, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jill P. Smith, Stephan Stern, Abdullah Mahmud
  • Methods for generation of pluripotent and multipotent cells
    Patent number: 11692175
    Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: July 4, 2023
    Assignee: The USA, as represented by, the Secretary, Department of Health and Human Services
    Inventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
  • Compounds that bind to human immunodeficiency virus rev response element
    Patent number: 11692010
    Abstract: Compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA are provided. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also provided are methods of treating or inhibiting HIV including administering one or more of the RRE binding compounds to a subject.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 4, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yun-Xing Wang, Ping Yu
  • CANNABINOID RECEPTOR MEDIATING COMPOUNDS
    Publication number: 20230202983
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Application
    Filed: September 29, 2022
    Publication date: June 29, 2023
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT
    Publication number: 20230203492
    Abstract: Disclosed herein are embodiments of a compound useful for treating or preventing betacoronavirus infections such as SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a betacoronavirus infection in the subject. The compound can comprise an oligomer comprising a nucleic acid base sequence that is antisense to at least a portion of a SARS-CoV-2 genomic RNA, and can comprise a sequence present in the 5? UTR and first 20 nt of coding sequence of the SARS-CoV-2 genomic RNA. The compound also can contain a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
    Type: Application
    Filed: November 7, 2022
    Publication date: June 29, 2023
    Applicants: Oregon State University, The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: Hong M. Moulton, David Adam Stein, Heinrich Ulrich Feldmann, Kyle Ture Rosenke
  • RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS
    Publication number: 20230201327
    Abstract: Provided is a polynucleotide encoding a respiratory syncytial virus (RSV) variant having an attenuated phenotype comprising a modified RSV genome or antigenome that encodes a mutant RSV protein P that differs from a parental RSV protein P at one or more amino acid residues. In some embodiments, the polynucleotide is recombinant. The invention also relates to methods of vaccinating an animal with the RSV variant or a pharmaceutical composition containing the RSV variant or inducing an immune response by administering the RSV variant to an animal, and further relates to methods of producing an RSV variant vaccine. In some embodiments, the animal is a human.
    Type: Application
    Filed: May 13, 2021
    Publication date: June 29, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Peter L. Collins, Cyril Le Nouen, Ursula J. Buchholz
  • Systems and methods to identify and treat subjects at risk for obstetrical complications
    Patent number: 11686735
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: June 27, 2023
    Assignees: WAYNE STATE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Tinnakorn Chaiworapongsa, Roberto Romero, Sonia S. Hassan
  • Stable water isotope labeling and magnetic resonance imaging for visualization of the presence of and prediction of the likelihood of occurence of rapidly dividing cells
    Patent number: 11684306
    Abstract: This disclosure generally relates to stable water isotope labeling followed by detection via MRI (swiMRI), including deuterium MRI (dMRI) and 17O MRI, for visualizing rapidly dividing immune cells within target and/or lymphoid organ/s and/or tissues affected by chronic graft-versus-host disease (cGVHD). Using deuterated water labeling, followed by dMRI, a distinction in deuterium signal was detected in a target organ (e.g. liver) of the cGVHD-affected mice compared to unaffected mice, i.e. syngeneic HSCT recipient mice, where the host and donor are matched, and normal (unmanipulated) mice.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 27, 2023
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES et al.
    Inventors: Nataliya Buxbaum, Donald Farthing, Martin Lizak, Helmut Merkle, Natella Maglakelidze, Brittany Oliver, Ronald Gress
  • Methods of producing enriched populations of tumor reactive T cells from peripheral blood
    Patent number: 11679128
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 20, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Monoclonal antibodies that specifically bind to matrilin 3 and their use
    Patent number: 11680093
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: June 20, 2023
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Systems and methods for three-dimensional fluorescence polarization via multiview imaging
    Patent number: 11680903
    Abstract: Systems and methods for three-dimensional fluorescence polarization excitation that generates maps of positions and orientation of fluorescent molecules in three or more dimensions are disclosed.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: June 20, 2023
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF CHICAGO, THE MARINE BIOLOGICAL LABORATORY
    Inventors: Hari Shroff, Abhishek Kumar, Shalin B. Mehta, Patrick Jean La Riviere, Rudolf Oldenbourg, Yicong Wu, Talon Chandler